Key TakeawaysRaymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform."The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in women.Lenacapavir and PBC treatment seladelpar could see combined annual sales of $3.7 billion by 2030, according to Raymond James' model. Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “m ...